A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients
Latest Information Update: 07 May 2024
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors NeuroDerm
- 16 Jun 2018 Results of this and another phase I study were presented at the 4th Congress of the European Academy of Neurology
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
- 20 Jun 2013 Status changed from active, no longer recruiting to completed.